Replies to post #59800 on Biotech Values

[genisi]

From Novartis' analyst meeting -
Sandoz has 25 biosimilars in varying stages of development and 110 ongoing difficult-to-make generics projects. Sandoz believes US guidance for biosimilars is near-term.